Oramed Pharmaceuticals vs Traws Pharma
ORMP and TRAW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ORMP and TRAW compare
Oramed Pharmaceuticals is the larger company, worth 40 times as much as Traws Pharma ($154M against $3.9M).
Oramed Pharmaceuticals pays a dividend yielding 6.7%; Traws Pharma does not pay one.
Oramed Pharmaceuticals scores higher on the StockData Score (12 against 5 for Traws Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ORMP | TRAW |
|---|---|---|
| Size and price | ||
| Market cap | $154M | $3.9M |
| Share price | $3.71 | $0.251 |
| Change, 1 year | 50.2% | −88.3% |
| Change, 5 years | −86.0% | −99.7% |
| Beta (5Y) | 1.42 | 1.19 |
| Employees | 13 | 7 |
| StockData Score | ||
| Total score | 12 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 1.1× | – |
| PEG | 0.04 | – |
| FCF yield | −2.1% | – |
| Growth | ||
| Revenue growth, 5Y average | −5.8% | 64.6% (better) |
| Net income growth (TTM) | 230% | – |
| EPS growth (TTM) | 241% | – |
| EPS growth, 5Y average | 12.8% | – |
| Profitability | ||
| Return on equity | 71.3% | – |
| Return on invested capital | −8.5% | – |
| Financial health | ||
| Current ratio | 6.07 (better) | 0.93 |
| Altman Z-score | 1.55 (better) | −85.39 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Dividend yield | 6.7% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | – | −109% |
| Shareholder yield | 6.7% (better) | −109% |
| Ownership | ||
| Held by institutions | 40.3% | 40.1% |
| Held by insiders | 23.9% | 35.7% |
| Insider net buying, 12 months | −$1.2M | $998K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 4.2% | 6.9% |
Go deeper
- ORMP stock overview
- ORMP income statement
- ORMP valuation and score
- TRAW stock overview
- TRAW income statement
- TRAW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.